Cytotoxicity of Eurycomanone and Fargesin in RAW 264.7 Murine Macrophages

Hanim Akmar Rosly¹, Amira Nabila Mat Roof¹, Salfarina Ramli¹,², Visarut Buranasudja³, Pornchai Rojsitthisak⁴,⁵, Boonchoo Sritularak⁴,⁶ and Hasseri Halim¹,²*

¹Faculty of Pharmacy, Universiti Teknologi MARA Selangor, Puncak Alam Campus, 42300, Bandar Puncak Alam, Selangor, Malaysia.
²Integrative Pharmacogenomics Institutes (iPROMISE), Universiti Teknologi MARA Selangor, Puncak Alam Campus, 42300, Bandar Puncak Alam, Selangor, Malaysia.
³Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
⁴Natural Products for Ageing and Chronic Diseases Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
⁵Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
⁶Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i41A32327

Editor(s):
(1) Dr. R. Deveswaran, M.S. Ramaiah University of Applied Sciences, India.

Reviewers:
(1) Ravi Prem Kalsait, Nagpur College of Pharmacy, India.
(2) Shaiju P.N, Fatima Mata National College, India.

Complete Peer review History: https://www.sdiarticle4.com/review-history/72086

Received 10 June 2021
Accepted 16 August 2021
Published 18 August 2021

ABSTRACT

Bioactive natural compounds derived from plants are the source for the development of new drugs. Numerous in vitro studies have explored the anti-inflammatory effect of eurycomanone and fargesin, derived from Eurycoma longifolia and Flosmagnoliae, respectively. However, before anti-inflammatory investigation is conducted, it is important to obtain the safe doses of these compounds to ensure the validity of the anti-inflammatory results. Therefore, the present study was

*Corresponding author: E-mail: hasseri2945@uitm.edu.my;
aimed to investigate the cytotoxicity of eurycomanone and fargesin towards macrophage RAW 264.7 cells to determine the safe doses of these compounds. Different concentrations of eurycomanone and fargesin were subjected to RAW 264.7 cells. The cytotoxicity of the compounds was evaluated by MTT assay and 50% inhibitory concentration (IC50) of these compounds was determined. Morphological changes of RAW 264.7 cells upon exposure to these compounds were also observed. Eurycomanone exhibited its cytotoxic effect by reducing RAW 264.7 cell viability dose-dependently with the IC50 of 94.17 µM. Meanwhile, fargesin had slight cytotoxicity towards RAW 264.7 cells with the IC50 of 173.5µM. Eurycomanone was more cytotoxic towards RAW 264.7 cells compared to fargesin. In conclusion, eurycomanone and fargesin at concentration up to 25 µM, was not toxic to the RAW 264.7 murine macrophages cells and the findings can be applied in the future anti-inflammatory study.

Keywords: Cytotoxicity; eurycomanone; fargesin; RAW 264.7 cells; IC50.

1. INTRODUCTION

Nature is the major source of bioactive compounds that are used in both traditional and modern medicines. For the past years, many drugs have been developed directly from bioactive natural compounds and plants are the most explored resources for the development of new drugs and pharmacological studies [1-4].

Drugs originated from plants used in treatment as anti-inflammatory, anticancerous, and analgesic, include acetylsalicylic acid (Aspirin), digoxin, paclitaxel, vincristine and morphine. For instance, Aspirin, is naturally occurring polyphenol that can be found in Salix sp. (Salicaceae). It has been used as an anti-inflammatory drug, whereas Paclitaxel, derived from Taxus brevifolia is an anticancer drug [5,6]. Hence, exploring the potential of a plant bioactive compound is paramount in the drug discovery and development.

Eurycoma longifolia is native to Malaysia, Indonesia, Vietnam, Cambodia, Laos, Myanmar and Thailand. Reported pharmacological activities including anticancerous, antimarial, anti-inflammatory, antioxidant, antimicrobial and aphrodisiac [7]. Most of the studies on E. longifolia focus on the anticancerous, anti-inflammatory and male fertility enhancement effect of the active compounds called eurycomanone[7-9].

Bioactive lignan from Flos magnoliae, fargesin is a Chinese herb that is used to treat sinusitis, allergic rhinitis, nasal congestion and headache. Previous studies also indicate that fargesin has anti-inflammatory, anti-allergy, antimicrobial and antidiabetic effects [10-13]. Most of the studies on fargesin derived from Flos magnoliae is on their anti-inflammatory effect [14-17].

Macrophages cells have been frequently used in the studies to elucidate the in inflammation process and anti-inflammation properties of interest compounds [18-24]. However, before any on anti-inflammatory investigation can be carried out, the cytotoxicity of compounds of interest towards macrophage cells need to be evaluated in order to determine the sub-lethal dose. Generally, cytotoxicity of a bioactive compound is indicated when the compound can alter cell morphology or metabolism, affect cell proliferation of induced cell death [25]. Therefore, the aim of this study was to assess the cytotoxicity of eurycomanone and fargesin on RAW 264.7 cells to identify safe dose of these compounds. The findings from this study can be applied in the future anti-inflammatory study.

2. MATERIALS AND METHODS

2.1 Materials and Reagents

Eurycomanone (catalog no.: CFN92008) and Fargesin (catalog no.: CFN98174) were purchased from Wuhan ChemFaces Biochemical Co., Ltd. (Wuhan, Hubei, China). Dulbecco’s modified Eagle’s Medium (DMEM) and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Massachusetts, USA) and Fischer Scientific (Paisley, UK), respectively. Phosphate buffer saline tablet was acquired from Sigma-Aldrich (Missouri, USA). Penicillin-Streptomycin Mixed Solution was purchased from NacalaiTesque, Inc., Kyoto, Japan while trypsin was obtained from Thermo Fisher Scientific (Denmark). All other chemicals were of analytical grade and made available from standard commercial suppliers.

2.2 Cell Culture

Murine macrophages, RAW264.7 cells (ATCC® TIB-71™) were obtained from American Type
Culture Collection (ATCC) (Virginia, United State). Cells were grown in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100 IU mL⁻¹ penicillin and 100 g mL⁻¹ streptomycin, incubated at 37 °C in a humidified atmosphere with 5% CO₂. The cells were cultured every week according to ATCC protocol.

2.3 Cytotoxicity of Different Concentrations of Eurycomanone and Fargesin

RAW 264.7 cells were treated with different concentrations of eurycomanone and fargesin (1.56 µM, 3.13 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, 100 µM and 200 µM) in order to evaluate the cytotoxicity of these compounds on the cells, hence determined the sub-lethal dose of these compounds for further study. RAW264.7 cells were seeded into 96-well plate for 24 hours, then the cells were treated with different concentrations of eurycomanone and fargesin for another 24 hours. After that, the cells were subjected for MTT assay and morphological observation.

2.4 Determination of Cell Viability by MTT Assay

Tetrazolium bromide salt (0.5 mg/mL of stock in PBS) was used to access the cytotoxic effect of eurycomanone and fargesin on the viability of RAW 264.7 cells. Basically, the test is used to assess the mitochondrial NADH-dependent dehydrogenase activity which is proportional to cell viability. After treatment, 100 µL of 0.5 mg/mL of tetrazolium bromide salt were added to the cells in the 96-well plate. Next, the plate was incubated for 3 hours at 37 °C in a humidified atmosphere with 5% CO₂. Then, the MTT solution was removed carefully and the insoluble formazan was dissolved in 100µL of dimethyl sulfoxide (DMSO) to each well. The absorbance values were measured at 570 nm using Multiwell micro-plate reader (Synergy HT, Bio-Tek Instruments, Inc. Vermont, USA). The untreated sets were also run under identical conditions and served as control.

2.6 Determination of IC₅₀ of Eurycomanone and Fargesin

IC₅₀ is the lethal dose of the compounds that is needed to kill half of the RAW 264.7 cells’ population. Cell viability’s results from the MTT assay were used to determine the IC₅₀ of eurycomanone and fargesin. Percentage mean values of cell viability were transferred into Prism 8 (Graphpad) and dose-response curve of the compounds were generated and analysed. Dose-response curves were parameterized by the log(concentration compounds) against response, which the response is the percent cell viability when compared to control. The IC₅₀ values were calculated using the non-linear regression analysis (curve fit).

2.7 Statistical Analysis

The results were expressed as mean ± standard deviation (SD) from at least three independent experiments between different concentrations of eurycomanone and fargesin. Student’s t-test was used to determine the significant difference between different concentrations of compounds with the control (0.5% DMSO). Microsoft Excel 2016 and Prism 8.0 (GraphPad) software were used for statistical analysis and determination of IC₅₀ of the compounds, respectively. p < 0.05 indicated significant differences.

3. RESULTS

3.1 Cell Viability of RAW 264.7 Cells upon Subsequent Exposure to Eurycomanone

Eurycomanone, quassinoids from E. longifolia, with concentration ranging from 0 µM to 200 µM concentration was subjected to macrophage RAW 264.7 cells and the cell viability was
assessed using MTT assay. Result in Fig. 1B shows that eurycomanone reduces RAW 264.7 cells viability dose-dependently. There was a dramatic decrease in RAW 264.7 cells viability from 100 µM to 200 µM. RAW 264.7 cells treated with 50 µM and 200 µM eurycomanone were statistically significant to control (0.5% DMSO) with the cell viability of 68% and 25%, respectively.

3.2 RAW 264.7 Cells Morphology upon Exposure to Eurycomanone

Microscopic digital camera was used to observe the morphology of RAW 264.7 cells. The images were recorded and digitized from the TopView application. Fig. 1c portrayed the RAW 264.7 cells upon exposure to distinct concentrations of eurycomanone. The macrophage cells morphology in DMEM and control (DMSO) portrayed a mixture of small, rounded, flattened and expanded cells. There were no signs of cell shrinkage and the cells were attached to the surface. Macrophage cells treated with 1.56 and 3.13 µM eurycomanone were no obvious difference of morphological characteristic than control cells. Macrophage cells treated with 6.25 and 12.5 µM of eurycomanone were more flattened and expanded compared to control cells which were smaller and rounded. There were few cells shrink and floating in media upon exposure to 25 and 50 µM eurycomanone. Treatment with 100 µM eurycomanone significantly changed the structural alterations and reduction cells population. The cells were less rounded, detach from the surface and float in the media.

3.3 IC$_{50}$ of Eurycomanone

IC$_{50}$ of eurycomanone was determined using Prism 8.0 (GraphPad). IC$_{50}$ is the toxic concentration of eurycomanone needed for 50% inhibition of cell viability. Fig. 1D portrayed the dose-response curve of eurycomanone. The IC$_{50}$ of eurycomanone is 94.17 µM, which means that 94.17 µM of eurycomanone was required to kill half of the macrophage’s cell population.

3.4 Cell Viability of RAW 264.7 Cells upon Subsequent Exposure to Fargesin

Fargesin, a bioactive lignan from *Flosmagnoliae*, ranging from 0 µM to 200 µM concentration was treated to macrophage RAW 264.7 cells and MTT assay was used to determine cell viability. Fig. 2B shows that fargesin had slight cytotoxic effects on RAW 264.7 cells up to 25 µM concentration with cell viability fluctuating between 90% to 100%. As the fargesin concentration elevated to 50 µM and 100 µM, the macrophage cell viability reduced to 85%. There was a sharp decrease in macrophage cell viability when fargesin concentration was increased to 200 µM. RAW 264.7 cells subjected to 50 µM and 200 µM fargesin were statistically significant to control (0.5% DMSO) with cell viability of 84.7% and 44.5%.

3.5 RAW 264.7 Cells Morphology upon Exposure to Fargesin

Morphology of RAW 264.7 cells were observed under a microscopic digital camera. The TopView application was used to record and digitize the images. Fig. 2B depicted RAW 264.7 cells after exposure to different concentrations of fargesin. Macrophage cells in this Fig. have a rounded and expandable cells which were attached on the surface.

Macrophage cells morphology treated with fargesin doses between 1.56 to 25 µM did not show much difference than control cells. As concentration of fargesin elevated (50 and 100 µM), the cells changed its shape to round and detached. Treatment with 200 µM fargesin resulted in dramatic morphological changes in the cells and decrease in cell population. Cell cytoplasmic shrinkage, reduction in size, and tendency to float in the medium after the treatment were observed.

3.6 IC$_{50}$ of Eurycomanone

Prism 8.0 (GraphPad) was used to determine the IC$_{50}$ of fargesin. It is the lethal concentration of fargesin required to inhibit 50% cell viability. Results in Fig. 2D represent the dose-response curve of fargesin. The IC$_{50}$ of fargesin is 173.5 µM. In other words, 173.5 µM of fargesin was needed to destroy half of the macrophages’s cell population.

4. DISCUSSION

Bioactive compounds specifically originate from plants have received major attention in the development of new drugs and pharmacological studies. *E. longifolia* and *M. fargesii* have been...
Fig. 1. Cytotoxicity of eurycomanone on RAW 264.7 cells. Briefly, the cells were seeded onto 96-well plate. After overnight, the cells were treated with various concentrations of eurycomanone (1.56-200µM), media and 0.5% DMSO (control) for 24 hours. Then the cells were subjected into MTT Assay. A. The structure of eurycomanone. B. The cell morphology after treatment. C. The cell viability after exposure to eurycomanone. D. Dose-response graph from Graphpad Prism software. IC\textsubscript{50} of eurycomanone is 94.17µM. *p<0.05, a statistically significant difference from untreated control (0.5% DMSO)

Fig. 2. Cytotoxicity of fargesin on RAW 264.7 cells. Briefly, the cells were seeded onto 96-well plate. After overnight, the cells were treated with various concentrations of fargesin (1.56-200µM), media and 0.5% DMSO (control) for 24 hours. Then the cells were subjected into MTT Assay. A. The structure of fargesin. B. The cell morphology after treatment. C. The cell viability after exposure to fargesin. D. Dose-response graph from Graphpad Prism software. IC\textsubscript{50} of fargesin is 173.5µM. *p<0.05, a statistically significant difference from untreated control (0.5% DMSO)
used for ages as herbal medicines and previous studies discovered that both of them exhibited anti-inflammatory effect. Eurycomanone and fargesin derived from *Eurycoma longifolia* and *Flosmagnoliae*, respectively are the compound of interest in this current study to discover their anti-inflammatory effect on macrophage RAW264.7 cells. Nevertheless, before further study on the anti-inflammatory effect of these compounds is conducted, it is essential to assess the cytotoxicity of both eurycomanone and fargesin on macrophage RAW264.7 cells.

The potential cytotoxicity of both eurycomanone and fargesin towards macrophage RAW 264.7 cells is evaluated by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. In the MTT assay, the IC<sub>50</sub> values obtained from the assay indicates the cytotoxicity effect of the compounds. This assay measures reduction of MTT into insoluble purple formazan in the mitochondria of living cells with the help of mitochondrial succinate dehydrogenase. Reduction of MTT into insoluble purple formazan can only occur in metabolically active cells. The insoluble purple formazan is dissolved with DMSO and spectrophotometer is used to measure the quantity of formazan which is directly proportional to the number of viable cells [26,27].

Most of the cytotoxic studies on eurycomanone derived from *E. longifolia* are about its cytotoxic effect towards cancer cells, which render this compound as a potential candidate for anticancer treatments [7]. In the current study, eurycomanone exhibited cytotoxic effect on RAW 264.7 cells with the IC<sub>50</sub> of 94.7 µM. A study by Miyake et al. discovered the cytotoxicity of eurycomanone on four cancer cell lines (colon 26-L5, IC<sub>50</sub> = >100 µM; B16-BL6 melanoma, IC<sub>50</sub> = 35 µM; Lewis lung carcinoma (LLC), IC<sub>50</sub> = >100 µM; human lung A549 adenocarcinomas, IC<sub>50</sub> = 5.8 µM) [28]. Results from previous studies indicate that eurycomanone showed selective cytotoxicity towards B16-BL6 and A549. The result shows that eurycomanone has a more cytotoxic effect on cancer cells line B16-BL6 and A549 compared to RAW 264.7 cells used in the current study. The difference between the cytotoxic effects might be due to the incubation period of the compound with the cells. Incubation periods of eurycomanone with the cancer cells is 72 hours while RAW 264.7 cells are incubated with eurycomanone for only 24 hours. This result indicates that long-term incubation of the cells with eurycomanone might lead to an increase in cytotoxicity.

Hajjouli et al. discovered that eurycomanone reduced cell viability of K562 and Jurkat human leukaemia cells dose- and time-dependently. Eurycomanone exhibited its cytotoxic effect on K562 and Jurkat leukaemia cells with IC<sub>50</sub> of 48.92 µM and 40.2 µM, respectively [8]. Similarly, the cell viability of RAW 264.7 cells also been reduced by eurycomanone dose-dependently. However, IC<sub>50</sub> of eurycomanone (94.7 µM) is higher compared to the IC<sub>50</sub> of K562 and Jurkat human leukaemia cells which shows that eurycomanone has a less cytotoxic effect on RAW 264.7 cell compared to the human leukaemia cells. A study by Hajjouli et al. and current study are conducted at the same incubation period of 24 hours [8].

Additionally, a study by Wong et al. highlights that eurycomanone can reduce the cell viability of human lung adenocarcinoma (A549) in a dose-dependent manner at IC<sub>50</sub> of 5.1 µM [29,30]. Eurycomanone decreased cell viability in a dose-dependent manner are in line with the current study and previous studies conducted by Wonget al. and Zakaria et al. on liver cancer cells (HepG2). Eurycomanone reduces the viability of HepG2 cells by 50% inhibition at 3.8±0.12 µM [9,29,30]. Both IC<sub>50</sub> of eurycomanone on A549 and HepG2 indicate that eurycomanone is more toxic towards these cells compared to macrophages RAW 264.7 cells. The discrepancy in results may be due to the incubation period of the cells with eurycomanone. A549 and HepG2 cells have been incubated for 72 hours while macrophage RAW 264.7 cells are incubated for only 24 hours. These indicate that the incubation period might contribute to the cytotoxic effects shown by eurycomanone.

Salahi et al. assessed the cytotoxicity of eurycomanone towards K562 human leukaemia cells and the compound inhibited the viability of K562 cell by 50% at the concentration of 6±1 µM [31]. Eurycomanone is more cytotoxic in K562 cells compared to RAW 264.7 cells in the current study and it could be due to the difference in incubation period between the cells. RAW 264.7 cells have been incubated for only 24 hours while K562 cells for 48 hours. Mahfudh and Hawariah studied the cytotoxic effect of eurycomanone on cancer cells, Coav-3, HeLa, HepG2, HM3KO and MCF-7 and discovered that eurycomanone can decrease the viability of those cancerous cells with IC<sub>50</sub> of 3.03±0.14 µM,
2.13±0.09 μM, 4.02±0.12 μM, 4.21±0.2 μM and 3.63±0.11 μM, respectively [32]. Eurycomanone is more cytotoxic towards these cancer cells compared to macrophages RAW 264.7 cells. Incubation time for cancer cells in the previous study and RAW 264.7 cells in the current study are, 72 hours and 24 hours, respectively. The inconsistency in the result indicates that long-term exposure of the cells to eurycomanone can lead to an increase in cytotoxicity.

Furthermore, a study by Thu et al. revealed that root extract of *E. longifolia* did not exert any cytotoxic effect on RAW 264.7 cells upon exposure to different concentration of *E. longifolia* root extract (1, 5, 25, 50 and 100 μM) for 24 hours. The viability of macrophages RAW 264.7 cells in the previous study is more than 95% [33]. The result from the previous study is inconsistent with the current study because, at a concentration of 50 μM, the viability of RAW 264.7 cells is less than 80%. The discrepancy of results might be due to the different type of RAW 264.7 cells used. The current study used RAW 264.7 cell without nitric oxide and the previous study might use parent RAW 264.7 cells. Other than that, current study specifically used eurycomanone which mostly can be found from the root of *Eurycoma longifolia* while the previous study used the root extract of the plant which might have the combination of eurycomanone with other quassinoids.

A study by Thuet et al. also discovered that long-term exposure to *E. longifolia* might cause intensification in cytotoxicity. Furthermore, a study by Tran et al. focus on the anti-inflammatory effect of eurycomanone on TNF-α stimulated HEK-293/NF-κB-luc cells. The inhibition of eurycomanone on NF-κB activity in the cells occur at IC₅₀ 2.4 μM [34]. This indicates that eurycomanone is more toxic in inhibiting biological function in TNF-α stimulated HEK-293/NF-κB-luc cells compared to biological function in RAW 264.7 cells.

In the current study, fargesin showed a cytotoxic effect on RAW 264.7 cells with the IC₅₀ of 173.5 μM. Jun et al. assessed cell viability of human metastatic breast cancer (MDA-MB-231) cells upon treatment with fargesin and viability of MDA-MB-231 cells decrease dose-dependently. This result contradicted with the current study because the viability of RAW 264.7 cells when treated with fargesin do not decrease in a dose-dependent manner. Also, a study by Jun et al. assess the ability of fargesin to inhibit osteoclasts process in bone marrow macrophages (BBM) dose-dependently with IC₅₀ of 4.33 μM [35]. The previous study shows that fargesin is more toxic in inhibiting the biological function of BBM compared to the biological function of macrophage RAW 264.7 cells in the current study. The discrepancy in result between the previous study and current study might be due to different type of macrophage cells used.

A study reported, Fargesin does not exert any toxicity on the viability of THP-1 monocytes cells up to 20 μM[18]. The result is in line with the current study because fargesin does not exhibit any toxic effect on RAW 264.7 cells viability up to the concentration of 20 μM Types of cells used might be the reason for a similar result. The previous study by [18] used the precursor of macrophages, monocytes while the current study used macrophages.

Moreover, a study by Jiménez-Arellanes et al. discovered the toxic effect of fargesin on *Entamoeba histolytica* strain HMI-IMSS and *Giardia lamblia* strain IMSS: 0989: 1 with IC₅₀ of 120.6 μM and 262.7 μM, respectively, hence render the ability of fargesin as an antiprotozoal [36]. The IC₅₀ of fargesin (173.5 μM) on RAW 264.7 cells are lower than the IC₅₀ of *Entamoeba histolytica* and *Giardia lamblia*, which indicate that fargesin is more toxic towards RAW 264.7 cells compared to these protozoans. A study by Kim et al. assessed the ability of fargesin to inhibit the production of nitric oxide (NO) by BV-2 microglial cells at IC₅₀ of 10.4±2.8 μM [15]. This result proves that fargesin is more toxic in inhibiting BV-2 microglial cells biological function compared to biological function in RAW 264.7 cells with the 1C₅₀ of 173.5 μM [15].

In the current study, IC₅₀ of eurycomanone (94.7 μM) is higher than fargesin (173.5 μM), which indicates that eurycomanone has more cytotoxic effect on RAW 264.7 cells compared to fargesin. Based on the dose-response curve of eurycomanone in Figure 1D, the safe dose for eurycomanone that can be used for further pharmacological study on RAW 264.7 cells are between the concentration of 1.56 μM to 12.5 μM. On the other hand, the dose-response curve of fargesin in Figure 2D indicates that the safe dose for fargesin on RAW 264.7 cells is between the concentration of 1.56 μM to 25 μM.

Cytotoxicity of eurycomanone is often associated with its anticancer activity. Eurycomanone exerts its anticancer activity mainly via antiproliferative
effect. Anticancer activity of eurycomanone has been contributed by the α,β-unsaturated ketone group present in the eurycomanone structure. The α,β-unsaturated ketone group also play a crucial role in anti-inflammatory activity through the inhibition of NF-κB pathway [8,37-40].

The underlying mechanism behind cytotoxicity of eurycomanone and its ability to initiate apoptosis (programmed cell death) is through the upregulation of p53 tumour suppressor protein and pro-apoptotic protein (Bax) with downregulation of anti-apoptotic protein (Bcl-2). Eurycomanone also increases the level of cytochrome C in the cytosol which lead to induction of apoptosis. Eurycomanone is also known to activate caspases, an apoptotic signalling cascade and inhibit NF-κB[29-32,41].

5. CONCLUSION

The results suggested that eurycomanone is cytotoxic towards macrophages RAW 264.7 cells in a dose-dependent manner. On the contrary, fargesin only exhibits cytotoxicity on RAW 264.7 cells when the concentration is more than 50 μM. Additionally, the IC_{50} of eurycomanone and fargesin are 94.17 μM and 173.5 μM, respectively. The results of this study prove that eurycomanone is more cytotoxic towards macrophages RAW 264.7 cells compared to fargesin. The cytotoxic effect of eurycomanone might be due to the presence of α,β-unsaturated ketone group in eurycomanone chemical structure. The underlying mechanism for eurycomanone cytotoxicity and its ability to induce apoptosis is might be via the upregulation of pro-apoptotic protein (Bax) and p53 tumour suppressor protein along with the downregulation of anti-apoptotic (Bcl-2). This compound can promote apoptosis by increasing the level of cytochrome C and active caspases, which is an apoptotic signalling cascade. Sub-lethal dose for eurycomanone and fargesin are 1.56 μM to 25 μM and 1.56 μM to 100 μM, respectively. Even though fargesin is not as cytotoxic as eurycomanone, it is still crucial to determine the sub-lethal dose of both compounds towards RAW 264.7 cells, so that a correct and accurate dose is used for further study to assess the anti-inflammatory effect of these compounds.

ACKNOWLEDGEMENT

The authors acknowledge the funder of this research, RMC UiTM, grant no. 600-IRMI 5/3/LESTARI (008/2019) and grant no. 600-RMI/DANA 5/3/RIF (735/2012).

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. BiochimBiophys Acta. 2013;1830(6):3670-95.
2. Harvey AL. Natural products in drug discovery. Drug Discov Today. 2008;13(19-20):894-901.
3. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629-61.
4. Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res. 2012;3(4):200-201.
5. López, V. “Are traditional medicinal plants and ethnobotany still valuable approaches in pharmaceutical research.” Latin American and Caribbean Bulletin of Medicinal and Aromatic Plants. 2011;10:3-10.
6. Hostettmann K, Marston A. Plants as a Still Unexploited Source of New Drugs. Natural Product Communications. 2008.
7. Rehman SU, Choe K, Yoo HH. Review on a traditional herbal medicine, Eurycoma longifolia Jack (Tongkat Ali): Its traditional uses, chemistry, evidence-based pharmacology and toxicology. Molecules. 2016;21(3).
8. Hajjouli S, Chateauvieux S, Teiten MH, Orlikova B, Schumacher M, Dicato M, et al. Eurycomanone and eurycomanol from Eurycoma longifolia Jack as regulators of signaling pathways involved in proliferation, cell death and inflammation. Molecules. 2014;19(9):14649-66.
9. Wong PF, Cheong WF, Shu MH, Teh CH, Chan KL, Abubakar S. Eurycomanone suppresses expression of lung cancer cell...
tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28. Phytomedicine. 2012;19(2):138-44.

10. Yusuf H, Satria D, Zulkarnain. The activity of eurycomanone derivatives on cancer cell lines. Int J Pharm Sci & Res. 2019;40:2947-50.

11. Solomon MC, Erasmus N, Henkel RR. In vivo effects of Eurycoma longifolia Jack (Tongkat Ali) extract on reproductive functions in the rat. Andrologia. 2014;46(4):339–48.

12. Chan KL, Low BS, Prashanta KD. The effect of Eurycoma longifolia on sperm quality of male rats. Natural Product Communications. 2009;4(10):1331-6.

13. Shen Y. Study on a Chinese herb Flosmagnoliae (Xin Yi) - identification and pharmacological actions Ye Shen (Doctor of Philosophy) Division of Chinese Medicine School of Health Sciences. RMIT University. 2007.

14. Id BY, Ren Y, Zhang J, Luo X, Yu Z, Ren G. Anti-inflammatory effects of fargesin on Chemically Induced Inflammatory Bowel Disease in Mice. Molecules. 2018;2:1–13.

15. Kim JS, Kim JY, Lee HJ, Lim HJ, Lee DY, Kim DH, et al. Suppression of inducible nitric oxide synthase expression by furfural lignans from flower buds of Magnolia fargesii in BV-2 microglial cells. Phyther Res. 2009;24(5).

16. Kim JY, Lim HJ, Lee DY, Kim JS, Kim DH, Lee HJ, et al. In vitro anti-inflammatory activity of lignans isolated from Magnolia fargesii. Bioorg Med Chem Lett. 2009;19(3):937–40.

17. Lee S, Ryu HW, Lee S, Shin I, Choi J. Lignans isolated from flower buds of Magnolia fargesii attenuate airway inflammation induced by cigarette smoke in vitro and in vivo. 2018;9:1–13.

18. Pham T, Kim M, Le M, Song Y, Bak Y, Ryu H, et al. Phytomedicine fargesin exerts anti-inflammatory effects in THP-1 monocytes by suppressing PKC-dependent AP-1 and NF-κBSignaling. Phytomedicine. 2017;24:96–103.

19. Porrutta I, Aquila S. The role of oxidative stress and autophagy in atherosclerosis. Oxid Med Cell Longev. 2015;2015:130315.

20. Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, et al. Oxidative stress-mediated atherosclerosis: Mechanisms and therapies. Front Physiol. 2017;8(AUG):1–16.

21. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nature Reviews Cardiology. 2015;10:7–10.

22. Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunol Rev. 2014;262(1):153–66.

23. Chistiakov DA, Bobryshev Y V, Nikiforov NG, Elizova N V, Sobenin IA, Orekhov AN. Macrophage phenotypic plasticity in atherosclerosis: The associated features and the peculiarities of the expression of inflammatory genes. International Journal of Cardiology. 2015;436–45.

24. Marchio P, Guerra-ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD. Review article targeting early atherosclerosis: a focus on oxidative stress and inflammation. 2019;2019(Ldl).

25. Rezk A, Al-Hashimi A, John W, Schepker H, Ullrich MS, Brix K. Assessment of cytotoxicity exerted by leaf extracts from plants of the genus Rhododendron towards epidermal keratinocytes and intestine epithelial cells. BMC Complement Altern Med. 2015;15(1):1–18.

26. Riss TL, Moravec RA, Niles AL, et al. Cell Viability Assays. 2013 May 1 [Updated 2016 Jul 1]. In: Markossian S, Grossman A, Brimacombe K, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences. 2004.

27. Feoktistova M, Gesericke P, Leverkus M. Crystal violet assay for determining viability of cultured cells. Cold Spring HarbProtoc. 2016;2016(4):pdb.prot087379.

28. Miyake K, Tezuka Y, Awale S, Li F, Kadota S, Quassinoids fromEurycoma longifolia. J Nat Prod. 2009;72(12): 2135-40.

29. Zakaria Y, Rahmat A, Hawariah A, Pihie L, Abdullah NR, Houghton PJ. Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53. Cancer Cell International. 2009:9:16.

30. Thu HE, Hussain Z, Mohamed IN, Shuid AN. Eurycoma longifolia, a potential phytomedicine for the treatment of cancer: evidence of p53-mediated apoptosis in cancerous cells. Curr Drug Targets. 2017;19(10):1109–26.

31. Al-Salahi OSA, JI D, Majid AMSA, Kit-Lam C, Abdullah WZ, Zaki A, et al. Anti-tumor activity of Eurycoma longifolia root extracts
32. Mahfudh N, Pihie AHL. Eurycomanone induces apoptosis through the up-regulation of p53 in human cervical carcinoma cells. J Cancer Mol. 2008;4(4):109–15.

33. Ei H, Hussain Z, Naina I, Nazrun A. *Eurycoma longifolia*, a promising suppressor of RANKL-induced differentiation and activation of osteoclasts: An *in vitro* mechanistic evaluation. J Ayurveda Integr Med. 2019;10(2):102–10.

34. Tran TVA, Malainer C, Schwaiger S, Atanasov AG, Heiss EH, Dirsch VM, et al. NF-κB inhibitors from *Eurycoma longifolia*. J Nat Prod. 2014;77(3):483–8.

35. Jun AY, Kim HJ, Park KK, Son KH, Lee DH, Woo MH, et al. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts. Invest New Drugs. 2014;32(1):1–13.

36. Jiménez-Arellanes A, León-Díaz R, Meckes M, Tapia A, Molina-Salinas GM, Luna-Herrera J, et al. Antiprotozoal and antimycobacterial activities of pure compounds from *Aristolochia elegans* rhizomes. Evidence-based Complement Altern Med. 2012.

37. Li Z, Ruan JY, Sun F, Yan JJ, Wang JL, Wang T, et al. Relationship between structural characteristics and plant sources along with pharmacology research of quassinoids. Chemical & Pharmaceutical Bulletin. 2019;67(7):654-65.

38. Low BS, Teh CH, Yuen KH, Chan KL. Physico-chemical Effects of the major quassinoids in a standardized *Eurycoma longifolia* extract (Fr 2) on the bioavailability and pharmacokinetic properties, and their implications for oral antimalarial activity. Nat Prod Commun. 2011;6(3):337–41.

39. Tung NH, Uto T, Hai NT, Li G, Shoyama Y. Quassinoids from the root of *Eurycoma longifolia* and their antiproliferative activity on human cancer cell lines. Pharmacogn Mag. 2017;13(51):459–62.

40. Chakraborty D, Pal A. Quassinoids: chemistry and novel detection techniques. In: Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes. Springer Berlin Heidelberg. 2013;3345–66.

41. Tee TT, Azimahtol HLP. Induction of apoptosis by *Eurycoma longifolia* Jack extracts. Anticancer Res. 2005;25(3B):2205–13.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/72086